Publication
Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma.
Anna Kuchnio, Danlin Yang, Nele Vloemans, Ivo Cornelissen, Ricardo Amorim, Tatiana Perova, Cassandra Lowenstein, Lut Janssen, Toon Suls, Mariette Bekkers, Elena Lasorsa, Lorena Fontan, Neeharika Nemani, Taylor Hojnacki, Chao Han, Siddharth Sukumaran, Nicole Medeiros, Srimathi Srinivasan, Bingyuan Wu, Jun Chen, Michael D Feldkamp, Sam Wu, Habtom Habte, Autumn J McRee, Nikki Daskalakis, John Krayer, Cam Holland, Ricardo Attar, Phillip M DeYoung, Sanjaya Singh, Yusri Elsayed, Ulrike Philippar
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260908-000002
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Despite advances in targeted therapies, in the majority of patients, relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) remains incurable. Thus, there is a critical need to expand the treatment options for R/R B-NHL to improve patient outcomes. In this study, we characterized JNJ-80948543,…
Read on PubMedLinked entities
Linked entities (3)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 2
- trialNCT05424822registry_reference1.00
- trialNCT06139406registry_reference1.00
Candidate 1
- cancerNon-Hodgkin Lymphomadictionary0.60
Registered trialsNCT05424822NCT06139406
Curated evidence
Evidence citing this paper (0)
Data not yet available